Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET

Company Participants

Ryan Crowe - Vice President, Investor Relations

Leonard Schleifer - Co-Founder, President and Chief Executive Officer

George Yancopoulos - Co-Founder, President and Chief Scientific Officer

Marion McCourt - Executive Vice President and Head, Commercial

Bob Landry - Executive Vice President and Chief Financial Officer

Conference Call Participants

Tyler Van Buren - Cowen

Matthew Harrison - Morgan Stanley

Carter Gould - Barclays

Brian Abrams - RBC Capital Markets

Evan Seigerman - BMO Capital Markets

Salveen Richter - Goldman Sachs

Mohit Bansal - Wells Fargo

Colin Bristow - UBS

Chris Raymond - Piper Sandler

Chris Schott - JPMorgan

Robyn Karnauskas - Truist

Operator

Welcome to the Regeneron Pharmaceuticals’ Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded. I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin.

Ryan Crowe

Thank you, Shannon. Good morning, good afternoon and good evening to everyone listening around the globe. Thank you for your interest in Regeneron and welcome to our fourth quarter 2022 earnings conference call. An archive of this webcast will be available on our Investor Relations website shortly after the call ends.

Joining me today are Dr. Leonard Schleifer, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Financial Officer. After our prepared remarks, we will then open the call up for Q&A.

I would like to remind you that remarks made on today’s call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and businesses, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement issues, intellectual property, pending litigation and other proceedings and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those projected in that statement.

A more complete description for these and other material risks can be found in Regeneron’s filings with the United States Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2022 which we expect to file with the SEC on Monday, February 6. Regeneron does not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. In addition, please note that GAAP and non-GAAP measures will be discussed in today’s call. Information regarding our use of non-GAAP financial measures and a reconciliation of those measures to GAAP is available in our financial results press release and our corporate presentation, which can be accessed on our website.